{
    "clinical_study": {
        "@rank": "156533", 
        "arm_group": [
            {
                "arm_group_label": "Dose-Escalation Phase", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dose-expansion cohort", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, Phase I study to evaluate the safety, tolera bility, and\n      PK of escalating doses of DLYE5953A administered to patients with in curable, locally\n      advanced, or metastatic solid malignancy that has progressed on standard therapy. The Phase\n      I study consists of two stages: Stage 1 dose-escala tion and Stage 2 expansion in selected\n      patients. In Stage 1, a 3 + 3 dose-escala tion design will be used to examine the safety,\n      tolerability, and PK of increasi ng doses of DLYE5953A. In Stage 2, patients will be\n      enrolled to further characte rize the safety, tolerability, and PK of the proposed dose and\n      schedule for futu re studies."
        }, 
        "brief_title": "A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >/= 18 years\n\n          -  ECOG performance status of 0 or 1\n\n          -  Histologically or cytologically documented advanced or metastatic solid tumors for\n             which established therapy either does not exist or has proven ineffective or\n             intolerable\n\n          -  Measurable disease by RECIST v1.1 with at least one measurable target lesion\n\n        Exclusion Criteria:\n\n          -  Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy,\n             oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except\n             palliative radiation to bony metastases), or herbal therapy as cancer therapy within\n             4 weeks prior to initiation of DLYE5953A\n\n          -  Oral kinase inhibitors approved by local regulatory authorities may be used within 2\n             weeks prior to initiation of DLYE5953A, provided that any clinically relevant\n             drug-related toxicity has completely resolved and prior approval is obtained from the\n             Medical Monitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092792", 
            "org_study_id": "GO29146"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose-Escalation Phase", 
                "description": "Escalating doses of DLYE5953A", 
                "intervention_name": "DLYE5953A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose-expansion cohort", 
                "description": "Administration of DLYE5953A at the recommended phase II dose (RP2D)", 
                "intervention_name": "DLYE5953A", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO29146 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1 to 21"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total exposure of the drug, defined as the area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }, 
            {
                "measure": "Incidence of anti-DLYE5953A antibodies", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }, 
            {
                "measure": "Objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }, 
            {
                "measure": "Duration of objective response", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 months"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}